Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules

Teva's generic Remeron (mirtazapine) will have only five months of marketing exclusivity from its approval date due to FDA's current interpretation of the trigger for first-to-file 180-day marketing exclusivity under the Waxman/Hatch Act, Teva reported in its Feb. 18 earnings teleconference